Open Accessibility Menu

COVID-19 Treatments for Health Professionals

Monoclonal Antibody Treatment

Since the arrival of the Omicron variant, Sotrovimab is the only monoclonal antibody still effective for the treatment of mild to moderate COVID-19. OU Health does not currently have this medication, but it may become available in the future. Locations that have this therapy available can be found here.

EVUSHELD is another Omicron-active monoclonal antibody available via an emergency use authorization (EUA). It may be given for Pre-Exposure Prophylaxis (PrEP) to reduce the risk of being infected with SARS-CoV-2 in individuals who are immunosuppressed or who cannot receive a vaccine due to valid contraindication. It is not indicated for Post-Exposure Prophylaxis nor for Treatment.

If you are an OU Health provider, and you have a patient who may benefit from EVUSHELD, please fill out this form and email to

Antiviral Medicines

Paxlovid and Molnupiravir are two oral antiviral medications approved with emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA) that can help treat COVID-19. OU Health has these available at Oklahoma Children's Hospital Pharmacy. Prescriptions can be written or sent electronically. Call (405) 271-2156 or fax to (405) 271-2158. For updates on how many courses of these medications are available at different sites, you can check COVID-19 Therapeutics Locator.

Paxlovid (nirmatrelvir and ritonavir)

Paxlovid is an oral antiviral medication used to treat mild-to-moderate COVID-19 in adults and children. Children must be 12 years of age and older, weighing at least 88 pounds. The FDA recently authorized the emergency use of PAXLOVID in patients with a positive COVID-19 test, and who are at high risk of progression to severe COVID-19. Paxlovid is authorized only for outpatient treatment of COVID-19 and should not be used longer than 5 consecutive days. It must be started within 5 days of the onset of symptoms. Paxlovid has many important drug-drug interactions which must be reviewed. Here is an online tool to help check for these drug interactions.


Molnupiravir is an oral antiviral medication with emergency use authorization (EUA) for outpatient treatment of mild-to-moderate COVID-19 in patients. Patients must be 18 years of age and older and are at risk for progression to severe disease. Due to decreased efficacy and teratogenicity, it is recommended fourth line for outpatient therapy. Molnupiravir is authorized only for outpatient treatment of COVID-19 and should not be used longer than 5 consecutive days.


Remdesivir is an injectable antiviral that is available at the OU Edmond COVID infusion clinic. It is now FDA approved for outpatient use to treat mild to moderate COVID-19 in patients at high risk for progression to severe COVID-19. It is infused daily for 3 days. Remdesivir is especially useful for patients who are unable to receive Paxlovid or Sotrovimab.

If you are an OU Health Provider and would like to order Remdesivir for a patient, please fill out this form and fax to the number on the form, or email to

See how you benefit from OU Health services in the community Learn More
Discover what patient-centered care means for you Learn More